Individualized Clinical Trial

Study candidates must have a diagnosis of cancer.
There must be no single, “best” treatment which is universally accepted for the candidate’s diagnosis and clinical situation. (There is seldom a situation in oncology where this is the case.)
The candidate must have viable tumor cells which are accessible by biopsy.
The candidate must be able to receive chemotherapy. This means that the candidate should be ECOG performance status 0 or 1 and has no contraindications for receiving traditional, cytotoxic chemotherapy, chemotherapy with anti-kinase “targeted” agents, or antiangiogenic agents.
The subject’s physician must be qualified and willing to administer the chemotherapy regimen which is identified through functional tumor cell profiling and to provide clinical reports. Alternatively, the candidate must be willing to receive treatment and/or evaluation from a participating investigator.

Consent to Anonymous Online Reporting

The candidate must agree to allow his or her physician to provide the study investigators with data concerning treatments and treatment results, to include extended follow-up, for analysis and online posting. Participants’ identities will be closely-guarded - anonymity will be strictly enforced in all online reporting. Coded identity numbers will be used in accordance with standard practice.

Financial Eligibility

An ethical consideration which the investigators impose upon themselves is the determination that no financial hardship should accrue to any patient. Patients who enter the study must be able to afford novel treatments which might be identified for them by comprehensive cell profiling. As a general guideline, we strongly advise that no patient enter this study if such involvement requires the acquisition of substantial debt, such as from loans, mortgages, or liquidation of assets. It is not our wish to deny any patient access to the study on purely economic grounds but we do advise that patients should be discouraged from entering this or any other clinical trial which inflicts financial difficulty.

For patients who do not qualify from a financial standpoint, we will strive to identify the best treatment outside the context of this clinical trial, using established, commercial CytoRx and EGFRx Functional Tumor Cell Profiling services.

As stated above, it is certain that the largest expense to the patient will be associated with the actual treatments – especially the drugs. These charges will be levied by the independent hospital, oncologist, or cancer center which administers the treatment. The Weisenthal Cancer Group derives absolutely no financial benefit from recommending any specific treatment. The Weisenthal Cancer Group charges only for its testing, therapy design, treatment coordination, and ongoing physician and patient support services.